CA2847336C - Glycosylated polypeptide and drug composition containing said polypeptide - Google Patents

Glycosylated polypeptide and drug composition containing said polypeptide Download PDF

Info

Publication number
CA2847336C
CA2847336C CA2847336A CA2847336A CA2847336C CA 2847336 C CA2847336 C CA 2847336C CA 2847336 A CA2847336 A CA 2847336A CA 2847336 A CA2847336 A CA 2847336A CA 2847336 C CA2847336 C CA 2847336C
Authority
CA
Canada
Prior art keywords
glycosylated
amino acids
ala
polypeptide
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2847336A
Other languages
English (en)
French (fr)
Other versions
CA2847336A1 (en
Inventor
Hirofumi OCHIAI
Taiji Shimoda
Kazuhiro Fukae
Masatoshi Maeda
Keisuke TAZURU
Kenta Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glytech Inc
Original Assignee
Glytech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glytech Inc filed Critical Glytech Inc
Publication of CA2847336A1 publication Critical patent/CA2847336A1/en
Application granted granted Critical
Publication of CA2847336C publication Critical patent/CA2847336C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
CA2847336A 2011-09-04 2012-09-03 Glycosylated polypeptide and drug composition containing said polypeptide Active CA2847336C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011192203 2011-09-04
JP2011-192203 2011-09-04
PCT/JP2012/072383 WO2013032012A1 (ja) 2011-09-04 2012-09-03 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Publications (2)

Publication Number Publication Date
CA2847336A1 CA2847336A1 (en) 2013-03-07
CA2847336C true CA2847336C (en) 2021-09-07

Family

ID=47756484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2847336A Active CA2847336C (en) 2011-09-04 2012-09-03 Glycosylated polypeptide and drug composition containing said polypeptide

Country Status (12)

Country Link
US (2) US9441024B2 (de)
EP (1) EP2752425A4 (de)
JP (2) JP6211418B2 (de)
KR (1) KR102175017B1 (de)
CN (2) CN103946234B (de)
AU (1) AU2012302637B2 (de)
BR (1) BR112014004936A2 (de)
CA (1) CA2847336C (de)
RU (1) RU2627184C2 (de)
SG (2) SG10201601327RA (de)
TW (1) TWI631142B (de)
WO (1) WO2013032012A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013022277B1 (pt) 2011-03-04 2021-08-03 Glytech, Inc Método para produção de cadeia de açúcar contendo ácido siálico
US9885832B2 (en) 2014-05-27 2018-02-06 Skorpios Technologies, Inc. Waveguide mode expander using amorphous silicon
US9977188B2 (en) 2011-08-30 2018-05-22 Skorpios Technologies, Inc. Integrated photonics mode expander
JP6211418B2 (ja) * 2011-09-04 2017-10-11 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
IN2014CN02399A (de) 2011-09-04 2015-06-19 Glytech Inc
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
AU2014236582B2 (en) 2013-03-14 2018-03-29 The University Of Massachusetts Methods of inhibiting cataracts and presbyopia
EP2970340B1 (de) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase-hemmer
US9664855B2 (en) 2014-03-07 2017-05-30 Skorpios Technologies, Inc. Wide shoulder, high order mode filter for thick-silicon waveguides
CR20180294A (es) 2015-11-13 2018-08-10 Univ Massachusetts Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
US10649148B2 (en) 2017-10-25 2020-05-12 Skorpios Technologies, Inc. Multistage spot size converter in silicon photonics
US11360263B2 (en) 2019-01-31 2022-06-14 Skorpios Technologies. Inc. Self-aligned spot size converter
CA3177889A1 (en) * 2020-06-02 2021-12-09 Sadasivan Vidyasagar Formulations and methods for treating diarrhea
CN116655906B (zh) * 2023-04-13 2024-03-29 大连理工大学 一种硫酸化糖多肽、制备方法及抗病毒应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380953A (en) 1978-09-11 1983-04-26 Filper Corporation Transfer mechanism in a peach pitter
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4280953A (en) * 1979-11-08 1981-07-28 The Salk Institute For Biological Studies Glycosylated analogs of somatostatin
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
LU85269A1 (fr) 1984-03-26 1985-10-14 Techland S A Composes nouveaux de somatostatine,procede pour leur synthese,preparation a usage veterinaire contenant lesdits composes et procede pour le traitement d'animaux
NL194729C (nl) 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
IT1277391B1 (it) * 1995-07-28 1997-11-10 Romano Deghenghi Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
FI965181A7 (fi) * 1996-12-20 1998-06-21 Map Medical Tech Oy Polyalkoholi-peptidijohdannaiset
JP3385947B2 (ja) 1998-01-05 2003-03-10 松下電器産業株式会社 バルクフィーダ
HU228811B1 (hu) * 2001-04-23 2013-05-28 Mallinckrodt Llc Technéciummal és réniummal radioaktívan jelölt, glikozilált oktreotidszármazékok
JP4323139B2 (ja) 2001-06-19 2009-09-02 康宏 梶原 糖鎖アスパラギン誘導体の製造方法
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
TWI335920B (en) 2002-12-24 2011-01-11 Yasuhiro Kajihara Sugar chain asparagine derivatives, sugar chain asparagine and sugar chain and manufacture thereof
TWI247749B (en) 2002-12-26 2006-01-21 Yasuhiro Kajihara 3 branch type saccharide chain asparagine derivative, saccharide chain asparagine there of, saccharide chain there of, and method for producing same
CN100378225C (zh) 2003-02-04 2008-04-02 大塚化学株式会社 糖链天冬酰胺衍生物的制造方法
JPWO2004101619A1 (ja) * 2003-05-15 2006-10-26 塩野義製薬株式会社 機能的糖ペプチドの合理的設計および合成
EP1650226A4 (de) 2003-07-28 2011-06-15 Yasuhiro Kajihara Aminierte zuckerkettenderivate vom komplexen typ und herstlelungsverfahren dafür
TWI466897B (zh) 2005-07-19 2015-01-01 Glytech Inc 癌細胞之檢測方法、糖鏈之構造解析方法，以及糖鏈衍生物
DK2225271T3 (da) * 2007-12-03 2013-10-07 Italfarmaco Spa Nye ikke-selektive somatostatin-analoger
JP2011512134A (ja) * 2008-02-19 2011-04-21 アステリオン・リミテッド 修飾リンカー
CA2727147A1 (en) 2008-06-17 2009-12-23 Otsuka Chemical Co., Ltd. Glycosylated glp-1 peptide
US20110118183A1 (en) 2008-06-27 2011-05-19 Novo Nordisk Health Care Ag N-glycosylated human growth hormone with prolonged circulatory half-life
IN2014CN02399A (de) 2011-09-04 2015-06-19 Glytech Inc
JP6211418B2 (ja) * 2011-09-04 2017-10-11 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Also Published As

Publication number Publication date
TWI631142B (zh) 2018-08-01
CN106146649A (zh) 2016-11-23
CA2847336A1 (en) 2013-03-07
US9802996B2 (en) 2017-10-31
JPWO2013032012A1 (ja) 2015-03-23
US9441024B2 (en) 2016-09-13
AU2012302637A1 (en) 2014-03-20
CN103946234A (zh) 2014-07-23
SG11201400293UA (en) 2014-08-28
BR112014004936A2 (pt) 2017-04-04
EP2752425A4 (de) 2015-04-22
US20160368961A1 (en) 2016-12-22
US20140315800A1 (en) 2014-10-23
JP6211418B2 (ja) 2017-10-11
CN106146649B (zh) 2020-09-01
WO2013032012A1 (ja) 2013-03-07
JP2017088615A (ja) 2017-05-25
KR20140060548A (ko) 2014-05-20
RU2627184C2 (ru) 2017-08-03
AU2012302637B2 (en) 2016-09-15
EP2752425A1 (de) 2014-07-09
TW201315743A (zh) 2013-04-16
CN103946234B (zh) 2017-06-30
RU2014112044A (ru) 2015-11-27
KR102175017B1 (ko) 2020-11-05
SG10201601327RA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
CA2847336C (en) Glycosylated polypeptide and drug composition containing said polypeptide
JP3983806B2 (ja) ソマトスタチンの環状ペプチド類似体
SI9420051A (en) Chemical modified peptide derivatives, process for their preparation and their use in human therapy
RU2361876C2 (ru) Пептидные векторы
US9937264B2 (en) Glycosylated polypeptide and drug composition containing said polypeptide
JP2016166206A (ja) ソマトスタチン−ドーパミンのキメラ類似体
MX2007013655A (es) Nuevos compuestos como agonistas glp-i.
AU1136000A (en) Cyclic peptide analogs of somatostatin

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170815

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260320

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260414